XML 36 R10.htm IDEA: XBRL DOCUMENT
v3.20.1

Net Loss Per Share | 3 Months Ended
--- | ---
Mar. 31, 2020
Earnings Per Share [Abstract] |
Net Loss Per Share | Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options, restricted stock units (RSUs), performance-based restricted stock units (PSUs), and shares related to convertible senior notes, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):
| Three Months Ended March 31,
| 2020 |  | 2019
Numerator: |  |  |
Net loss | $ | (5,713 | ) |  | $ | (4,318 | )
Denominator: |  |  |
Weighted average shares used to compute net loss per share, basic and diluted | 122,428 |  |  | 116,730 |
Net loss per share, basic and diluted | $ | (0.05 | ) |  | $ | (0.04 | )
The following potential weighted-average shares of common stock outstanding were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive (in thousands):
| Three Months Ended March 31,
| 2020 |  | 2019
Options to purchase common stock | 1,050 |  |  | 3,258 |
RSUs and PSUs | 3,316 |  |  | 6,732 |
Shares related to convertible senior notes | 3,968 |  |  | 3,332 |
Employee stock purchase plan | 10 |  |  | 41 |
Total common stock equivalents | 8,344 |  |  | 13,363 |
Shares related to convertible senior notes represents the anti-dilutive impact of our issuance of $345 million in aggregate principal amount of our 2023 notes as the average price of our common stock during the three months ended March 31, 2020 and 2019 was higher than the conversion price of $26.95. While these shares are anti-dilutive during the three months ended March 31, 2020 and 2019, they may be dilutive in periods we report net income. However, as a result of the capped call transactions, there will be no economic dilution from the 2023 notes up to $40.68, as exercise of the capped call instruments will reduce dilution from the 2023 notes that would have otherwise occurred when the average price of our common stock exceeds the conversion price. None of the shares related to our issuance of $800 million in aggregate principal amount of our 2025 notes were anti-dilutive during the three months ended March 31, 2020 and 2019. The average price of our common stock during the three months ended March 31, 2020 and 2019 was lower than the conversion price of our 2025 notes of $51.56.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration